Global Processing Services Welcomes Three Independent Non-Executive Directors to Its Board
23.2.2023 08:00:00 EET | Business Wire | Press release
Global Processing Services (“GPS”), a fast-growing next-gen global payments technology platform, today announced the appointment of Paulette Rowe, Shane Happach, and Lynn McCreary as independent Non-Executive Directors.
Paulette Rowe is one of the most influential women in payments, recognised by American Banker in its annual honours list for three consecutive years, and was formerly CEO of Paysafe’s Integrated and Ecommerce Solutions (IES) division. Paulette brings a wealth of experience across card-based and virtual wallet payment solutions. Prior to Paysafe, Paulette was Head of Payments and Financial Services Partnerships for Facebook and held senior roles in a variety of financial organisations over a 20-year period, including Barclaycard, Royal Bank of Scotland (RBS), Tesco Bank, and GE Capital.
Shane Happach is an experienced global payments executive with strengths in enterprise sales and fintech-led disruption. Shane was recently named as CEO of Singapore-based fintech, Coda Payments. Prior to Coda, Shane was CEO of payments fintech Mollie for two years, and spent more than a decade at Worldpay, where he held a number of senior positions, including EVP, Head of Global Ecommerce and Chief Commercial Officer. Before Worldpay, he worked with GlobalCollect – acquired by Ingenico in 2014 – in business development roles across the Americas and EMEA.
Lynn McCreary brings over three decades of experience in legal, business and executive leadership roles to GPS, having worked at financial services and payments firm Fiserv for 11 years, serving as Chief Legal Officer since 2013. Her responsibilities at Fiserv included directing the firm’s global legal, ethical and compliance activities, as well as taking an active role in coordinating its M&A strategy. Prior to joining Fiserv, Lynn was an equity partner at Bryan Cave LLP, now Bryan Cave Lighton Paisner, where she represented the interests of financial services companies, insurance companies, retailers and others in a broad range of commercial disputes. Lynn is currently Chief Legal Officer of Sportradar.
“Paulette, Shane and Lynn bring a wealth of experience to our Board and will support our team to capitalise on the enormous potential for disruption in the issuer processing space,” said Gene Lockhart, Chair of GPS. “GPS is committed to investing for the long-term to support our clients in accelerating innovation, diversifying product capabilities and facilitating new payments programmes worldwide.”
GPS has attracted a number of highly experienced global payments executives under the leadership of Kevin Schultz as Chief Executive Officer since July 2022. The company most recently announced the appointment of Visa veteran Jim McCarthy as Executive Vice President – Global Product and Sales, who has more than 30 years of payments experience; Kevin Fox as Chief Revenue Officer, and Jeff Burns as Chief Financial Officer.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230222005772/en/
Contact information
Louisa Bartoszek
Head of Communications, GPS
Louisa.bartoszek@globalprocessing.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Zynyz ® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 16:29:00 EET | Press release
Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “Today’s positive CHMP opinion is an important step towards addressing the urgent need for new treatment options for patients in Europe with advanced SCAC, a disease which has seen limited innovation for decades,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved, Zynyz in combination with platinum-based chemotherapy has the potential to become a new standard-of-care for patients living with this rare and difficult-to-treat cancer.” The positive CHMP opinion was based on data from the Phase 3 POD1UM-303/Inter
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 14:32:00 EET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 10:00:00 EET | Press release
With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerful, secure, reliable, and intelligent digital signage,” said Steve Durkee, chief executive office
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 09:30:00 EET | Press release
Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, supported by one of the largest bodies of published clinical data backed by decades of clinica
Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 09:00:00 EET | Press release
Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets. “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.” Throughout his career, Dan has held senior leadership roles i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
